CHICAGO, Dec. 29, 2025 (GLOBE NEWSWIRE) — Professional Diversity Network, Inc. (Nasdaq: IPDN) (“IPDN” or the “Company”), a technology holding company focused on the application of AI technologies and AI-powered solutions, today announced that it has completed a strategic investment in Deeptrade Token (DTT), the native platform token of DeeptradeX.AI, with a total transaction value of approximately US$2.59 million. This investment represents a further step in IPDN’s ongoing strategy to expand its presence in artificial intelligence (AI), digital asset, and Web3.0 sectors, which will reinforce the Company’s long-term commitment to next-generation intelligent financial technologies. DeeptradeX.AI is an innovative technology company focused on intelligent investment and automated trading solutions. By leveraging advanced AI algorithms...

GIG HARBOR, Wash., Dec. 29, 2025 (GLOBE NEWSWIRE) — IP Strategy (Nasdaq: IPST) (the “Company”), a digital intellectual property (DIP) company and the first public company to adopt a treasury reserve centered on the $IP token, today announced that it terminated its open Securities Purchase Agreement for its $15 million Equity Line of Credit (“ELOC”) originally entered in January 23, 2025. The cancellation of the ELOC was effective at the end of the trading day, Monday December 22, 2025 and no further purchases or puts were executed under the ELOC prior to termination of the Securities Purchase Agreement and cancellation of the ELOC. “As we look at the needs of our business going forward, and to assure the market that we are not intent on further dilutive instruments at this time, we feel that the continued effectiveness of the ELOC...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of improvements in bone mineral density with strong statistical significance The Company will implement significant expense reductions NOVATO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). Neither study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively. Both studies achieved the secondary endpoints of improvements in bone mineral density (BMD) against comparators....

Austin, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) — Digital Brands Group, Inc. (NASDAQ:DBGI) (the “Company,” “Digital Brands Group” or “DBG”) today announced he company has been added to the S&P Total Market Index (TMI), effective December 21, 2025. The S&P TMI is one of the broadest equity benchmarks published by S&P Dow Jones Indices, encompassing all major U.S. companies with readily available float-adjusted market capitalization data. Inclusion in the index reflects Digital Brands Group’s qualification under S&P’s eligibility methodology and marks a key milestone in the company’s continued growth and market recognition. “Being included in the S&P Total Market Index is another important validation of Digital Brands Group’s progress and visibility in the U.S. capital markets,” said Hil...

With legacy overhang removed and new capital secured, management shifts focus from balance-sheet repair to disciplined growth execution. West Palm Beach, FL, Dec. 29, 2025 (GLOBE NEWSWIRE) — QHSLab Inc. (the “Company”) (OTCQB: USAQ), a healthcare technology company focused on digital medicine and population health innovation, today announced the completion of a $500,000 private placement with accredited investors, providing fresh growth capital and further strengthening the Company’s balance sheet following the recent repurchase and retirement of its legacy convertible debt. This capital injection follows QHSLab’s November 2025 purchase and retirement of more than $1.4 million of legacy convertible notes issued in 2021 and 2022. Those notes carried 18 percent default interest and conversion rights at $0.20 per share, representing...

Neve Yarak, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) — N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, today announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. (“Solterra”). Key milestones in Germany and Italy have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality. Key Investor HighlightsPermitting Risk Reduced: Strong progress with zero objections in Germany’s public consultation and formal planning submissions in Italy, delivering enhanced visibility to approvals. Over $1.69 Million in Value Creation: Strategic renegotiation in Germany optimizes returns through disciplined, capital-efficient...

TOKYO, Dec. 29, 2025 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (Headquarters:Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or the “Company”), a diversified healthcare company, collaborating with World Foundation and Tools for Humanity to deploy Proof of Human technologies such as World ID throughout Japan. The World project was co-created by Sam Altman and Alex Blania. In preparation for the full-scale rollout of the World project in Japan, MEDIROM has entered into a Master Service Agreement (“MSA”) with Tools for Humanity (“TFH”) and World Foundation (“WF”). Under the MSA, the MEDIROM Group will be responsible for the operation of “Proof of Human” verification locations in Japan. This initiative is expected to contribute to MEDIROM’s revenue through operation fees and related services over time. Leveraging...

Next steps entail discussions on a potential POC project for integrating Foresight’s terrain intelligence into Audi’s vehicle development program Ness Ziona, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced that it was invited by Audi AG (“Audi”), one of the world’s most reputable car manufacturers, to participate in the Audi startup event “Minds and Makers”, organized by its partnering team. This technology innovation event brings together selected startups to present breakthrough solutions and explore future collaboration opportunities with Audi’s innovation teams. Foresight was selected to demonstrate its terrain intelligence solution. The solution provides real-time 3D analysis of various terrains,...

Company AnnouncementGenmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and increasingly competitive landscape This decision does not impact Genmab’s full‑year 2025 financial guidanceCOPENHAGEN, Denmark; December 29, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating opportunities in its late‑stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY® (epcoritamab),...